BLLN News & Events

Reports Q4 revenue $96.05M, consensus $87.2M. "2025 demonstrated how the compounding power of a differentiated technology platform, category-defining products, and disciplined execution can produce an extraordinary outcome," said Oguzhan Atay, co-Founder and CEO of BillionToOne. "With new prenatal and oncology products already launched, expanding payer coverage, and a growing base of providers choosing our tests, we are executing to solve the hardest problems in healthcare and give patients the answers they need. Entering 2026, we believe we are still in the earliest chapters of what is possible, and remain confident that our smNGS platform will continue to unlock diagnostic capabilities that transform patient lives one molecule at a time."

Consensus $396.73M. The company said, "BillionToOne now expects full year 2026 total revenue of $430 million to $445 million, representing growth of 41% to 46% compared to full year 2025. This compares to the company's previous guidance of $415 million to $430 million. BillionToOne also expects positive GAAP operating income for the full year 2026."

BillionToOne announced a collaboration with Epic, a comprehensive electronic health record. The agreement will integrate BillionToOne's prenatal and oncology testing portfolio with Epic's Aura diagnostics suite. Through the integration, clinicians will be able to order BillionToOne's UNITY Complete prenatal test as well as Northstar Select and Northstar Response liquid biopsy tests directly within Epic. Discrete test results then flow back into the electronic health record, where they can power downstream clinical decision support.